基线合并用药可能改变检查点抑制剂的抗肿瘤疗效及免疫相关不良事件风险
本研究纳入2015年5月至2017年9月接受ICI治疗的635例晚期癌症患者,回顾性分析ICI首次给药前1个月或后1个月内合并用药。基线使用抗生素、糖皮质激素>10 mg/天、PPIs、精神药物、吗啡和胰岛素与总生存期显著缩短和肿瘤缓解降低相关,而他汀类、ACE抑制剂和/或ARBs、NSAIDs、阿司匹林和口服降糖药不影响患者结局。改变ICI应答的治疗也与irAEs发生率降低相关。
要点
- 基线使用抗生素、糖皮质激素>10 mg/天、PPIs、精神药物、吗啡和胰岛素与ICI治疗患者总生存期缩短和肿瘤缓解降低相关。
- 他汀类、ACE抑制剂和/或ARBs、NSAIDs、阿司匹林和口服降糖药未显示对患者结局的负面影响。
- 改变ICI应答的合并用药也与免疫相关不良事件发生率降低相关。
核心结论
- ICI启动时必须仔细评估合并用药,临床医生应意识到其可能的有害效应,尤其是PPIs、糖皮质激素、抗生素和精神药物。
研究设计与样本
- 回顾性研究,纳入2015年5月至2017年9月在本机构接受ICI治疗的635例晚期癌症患者,从医疗记录中审查ICI首次给药前1个月或后1个月内的合并用药。
主要发现
- 基线使用抗生素、糖皮质激素>10 mg/天、PPIs、精神药物、吗啡和胰岛素与总生存期显著缩短和肿瘤缓解降低相关。
- 合并使用他汀类、ACE抑制剂和/或ARBs、非甾体抗炎药、阿司匹林和口服降糖药未影响患者结局。
- 改变ICI应答的治疗也与irAEs发生率降低相关。
- 因子分析混合数据(FAMD)揭示了各因素或合并用药对肿瘤学结局的各自权重。
临床怎么用
- 在启动ICI治疗时,应仔细评估合并用药,特别是PPIs、糖皮质激素、抗生素和精神药物,并警惕其可能的不良影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: As gut microbiota composition is an important determinant of response to immune checkpoint inhibitors (ICIs), we examined the effect of various co-medications known for their interaction with microbiota, when given at ICI initiation. PATIENTS AND METHODS: We identified patients with advanced cancer treated with ICI between May 2015 and September 2017 in our institution. Co-medications given within 1 month before or 1 month after the first administration of ICI were reviewed from medical records. Survival data were analysed with univariable Cox regression, and the combined effect of multiple factors was assessed with factor analysis of mixed data (FAMD). The impact of co-medications on immune-related adverse events (irAEs) occurrence was also assessed. RESULTS: A total of 635 patients were included. Psychotropic drugs (41%), proton pump inhibitors (PPIs; 38%), angiotensin-converting enzyme (ACE) inhibitors and/or angiotensin II receptor blockers (ARBs; 32%), glucocorticoids (26%), antibiotics (24%), statins (21%) and morphine (20%) were the most prescribed co-medications. Baseline use of antibiotics, glucocorticoids >10 mg/day, PPIs, psychotropic drugs, morphine and insulin was associated with significantly shortened overall survival and decreased tumour response, whereas coadministration of statins, ACEs and/or ARBs, non-steroidal anti-inflammatory drugs, aspirin and oral antidiabetic drugs did not impact patient outcomes. Treatments that altered the response to ICI were also associated with a decreased incidence of irAEs. FAMD revealed the respective weight of each factor or co-medication on the oncological outcomes. CONCLUSION: Co-medications must be carefully assessed at the time of ICI initiation and clinicians aware of their possible deleterious effect, notably for PPIs, glucocorticoids, antibiotics and psychotropic drugs.
引用
- Kostine M, Mauric E, Tison A, et al. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. Eur J Cancer. 2021. PMID: 34649118. doi:10.1016/j.ejca.2021.08.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。